Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Chronic Venous Disease during Pregnancy Is Related to Inflammation of the Umbilical Cord: Role of Allograft Inflammatory Factor 1 (AIF-1) and Interleukins 10 (IL-10), IL-12 and IL-18

  • Sánchez-Trujillo, Lara et al.
  • Ortega, Miguel
  • León Luis, Juan Antonio
  • Bravo Arribas, Coral
Chronic venous disease (CVD) is a common condition that affects the veins in the lower limbs, resulting in a variety of symptoms, such as swelling, pain, and varicose veins (VVs). The plenty hormonal, hemodynamic and mechanical changes occurred in pregnancy make women especially vulnerable to suffer from this condition in this period. Previous works have identified that CVD is associated with an increased inflammatory milieu and significant damage in maternofetal tissues, such as the umbilical cord. However, the inflammatory status of this structure in these patients has not been studied yet. Thus, the aim of the present study was to examine gene and protein expression of a set of inflammatory markers—Allograft inflammatory factor 1 (AIF-1), the proinflammatory cytokines interleukin 12A (IL-12A) and IL-18 and the anti-inflammatory product IL-10—in the umbilical cord of women with CVD during pregnancy (N = 62) and healthy pregnant women (HC; N = 52) by the use of real time qPCR and immunohistochemistry (IHC). Our results demonstrate that the umbilical cord tissue from CVD women exhibit an increased expression of AIF-1, IL-12A and IL-18 along with a decrease in IL-10. Therefore, our study suggests an inflammatory status of this structure related to CVD. Further studies should be conducted to evaluate the expression of other inflammatory markers, as well as to analyze the maternofetal impact of these findings.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endolysosomal remodeling and acidity dictates ferroptosis sensitivity to iron oxide nanoparticles

  • Daviu, Neus
  • Irigaray-Moreno, Alberto
  • Graciano-Casero, Carla
  • Barber, Domingo F.
Iron oxide nanoparticles (IONPs) exhibit remarkable anti-tumoral activity, largely mediated by the generation of reactive oxygen species (ROS). Although certain IONPs can induce ferroptosis, the determinants underlying cell-type-specific sensitivity remain poorly understood. Here, we provide novel mechanistic insight by demonstrating that lysosomal acidity and plasticity critically regulate iron mobilization, ROS compartmentalization, and the ferroptotic response triggered by dimercaptosuccinic acid-coated IONPs (DMSA‑IONPs) in MDA‑MB‑231 breast cancer and U87MG glioma cells. DMSA-IONPs generate ROS in both cell models, however, their subcellular localization markedly differed. In MDA-MB-231 cells, highly acidic lysosomes retained redox-active iron (Fe2+), leading to localized ROS accumulation, lysosomal enlargement and pronounced lipid peroxidation, ultimately inducing ferroptosis, which was reverted by the anti-ferroptosis drug Ferrostatin-1. In contrast, the less acidic lysosomes of U87MG cells released iron into the cytosol and mitochondria, resulting in diffuse ROS production without lipid peroxidation and conferring resistance to ferroptosis despite higher nanoparticle uptake. While IONP‑mediated ROS generation via iron mobilization and Fenton‑like reactions is well established, our findings identify lysosomes as critical determinants of cellular responses to IONPs exposure. Specifically, lysosomal acidity and endolysosomal trafficking govern ferroptotic sensitivity to IONPs by controlling the site of ROS accumulation. Our results demonstrate that IONP-induced ferroptosis depends not only on total ROS levels but also on ROS subcellular distribution, with ROS accumulated in lysosomes triggering lipid peroxidation of these organelles. These insights highlight the importance of evaluating lysosomal physiology across tumor type to optimize nanoparticle-based ferroptosis therapies, particularly for tumors resistant to apoptosis., This work was supported by grants to D.F. Barber: PID2020–112685RB-I00 from MCIN/AEI/10.13039/501100011033; PID2023–146210B-I00 from MCIN/AEI/10.13039/501100011033, and by the ERDF, EU; and S2022/BMD−7321 from the Madrid Regional Government (Comunidad de Madrid). N. Daviu was first a predoctoral scholar [FPU18/04828] funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”, and she then received a predoctoral scholarship funded by the PID2020–112685RB-I00 grant and subsequently a postdoctoral scholarship funded by the PID2023–146210B-I00 grant. A. Irigaray-Moreno was first a master's thesis student of the Biomolecules and Cell Dynamics Masters course at the Universidad Autónoma de Madrid, and he was then awarded a JAE-Intro ICU scholarship (JAEICU_24_00026) by the Nanomedicine CSIC HUB. C. Graciano-Casero was a master's thesis student on the Clinical Biotechnology Master's Degree of the European University of Madrid. This research work was performed in the framework of the Nanomedicine CSIC HUB and the Cancer CSIC HUB. The Centro Nacional de Biotecnología (CNB-CSIC) is a Severo Ochoa Center of Excellence (CEX2023–001386-S) funded by MICIU/AEI /10.13039/501100011033., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023–001386-S)., Peer reviewed